(GNFT) Genfit S.A. - Ratings and Ratios
Elafibranor, NIS4, VS-01, GNS561
Description: GNFT Genfit S.A.
Genfit S.A. is a late-stage biopharmaceutical company focused on discovering and developing treatments for metabolic and liver-related diseases, including primary biliary cholangitis, nonalcoholic steatohepatitis (NASH), and cholangiocarcinoma (CCA). The companys pipeline includes several promising candidates, such as Elafibranor, NIS4 technology, VS-01, GNS561, and SRT-015.
From a business perspective, Genfit has established strategic partnerships, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test, and a collaboration with Genoscience Pharma to develop and commercialize GNS561 for CCA. These partnerships demonstrate the companys ability to leverage its research and development capabilities to drive growth and create value.
To evaluate Genfits performance, key performance indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate are essential. Given the companys late-stage pipeline and partnerships, investors should monitor the progress of Elafibranor in Phase III clinical trials and the commercialization of NASHnext. Additionally, metrics like the number of patients enrolled in ongoing trials and the timeline for expected milestones can provide insight into the companys potential for future growth.
From a financial perspective, Genfits market capitalization stands at €165.28M, with a forward P/E ratio of 7.55, indicating a relatively high growth expectation. The companys return on equity (RoE) is -8.46, highlighting the significant investment required to drive its pipeline forward. As a trading analyst, it is crucial to monitor the companys cash reserves, burn rate, and funding plans to ensure that Genfit can continue to execute on its development plans.
To further assess Genfits potential, it is essential to track the progress of its pipeline candidates, particularly Elafibranor and GNS561, and monitor the competitive landscape in the biopharmaceutical industry. By analyzing these factors, investors can make informed decisions about the companys potential for long-term growth and returns.
GNFT Stock Overview
| Market Cap in USD | 205m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2006-12-19 |
GNFT Stock Ratings
| Growth Rating | -25.1% |
| Fundamental | 44.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -24.5% |
| Analyst Rating | - |
GNFT Dividends
Currently no dividends paidGNFT Growth Ratios
| Growth Correlation 3m | 28.5% |
| Growth Correlation 12m | -55.4% |
| Growth Correlation 5y | -6.6% |
| CAGR 5y | -3.14% |
| CAGR/Max DD 5y | -0.06 |
| CAGR/Mean DD 5y | -0.10 |
| Sharpe Ratio 12m | -0.09 |
| Alpha | -26.17 |
| Beta | 0.865 |
| Volatility | 41.14% |
| Current Volume | 93.4k |
| Average Volume 20d | 125.6k |
| Stop Loss | 3.2 (-7.2%) |
| Signal | 0.55 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (-6.53m TTM) > 0 and > 6% of Revenue (6% = 5.17m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 39.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 20.42% (prev 388.6%; Δ -368.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.27 (>3.0%) and CFO -40.5m <= Net Income -6.53m (YES >=105%, WARN >=100%) |
| Net Debt (-19.7m) to EBITDA (3.26m) ratio: -6.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.7m) change vs 12m ago -0.08% (target <= -2.0% for YES) |
| Gross Margin 95.61% (prev 98.51%; Δ -2.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 49.93% (prev 11.80%; Δ 38.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.12 (EBITDA TTM 3.26m / Interest Expense TTM 8.08m) >= 6 (WARN >= 3) |
Altman Z'' -12.43
| (A) 0.12 = (Total Current Assets 92.8m - Total Current Liabilities 75.2m) / Total Assets 151.4m |
| (B) -2.58 = Retained Earnings (Balance) -390.6m / Total Assets 151.4m |
| warn (B) unusual magnitude: -2.58 — check mapping/units |
| (C) 0.01 = EBIT TTM 940.6k / Avg Total Assets 172.7m |
| (D) -4.60 = Book Value of Equity -377.7m / Total Liabilities 82.2m |
| Total Rating: -12.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 43.95
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 9.48% = 4.74 |
| 3. FCF Margin 16.50% = 4.12 |
| 4. Debt/Equity 0.82 = 2.17 |
| 5. Debt/Ebitda 17.53 = -2.50 |
| 6. ROIC - WACC -7.23% = -9.03 |
| 7. RoE -8.46% = -1.41 |
| 8. Rev. Trend -13.89% = -0.69 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 2.21% = 0.06 |
| 11. EPS CAGR -47.53% = -2.50 |
What is the price of GNFT shares?
Over the past week, the price has changed by +2.56%, over one month by +3.48%, over three months by -8.74% and over the past year by -9.20%.
Is Genfit S.A. a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GNFT is around 3.08 EUR . This means that GNFT is currently overvalued and has a potential downside of -10.72%.
Is GNFT a buy, sell or hold?
What are the forecasts/targets for the GNFT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.5 | 174.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 3.4 | -1.2% |
GNFT Fundamental Data Overview
Market Cap EUR = 174.7m (174.7m EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 81.8m EUR (last quarter)
P/E Trailing = 115.0
P/E Forward = 344.8276
P/S = 2.4711
P/B = 2.5166
Beta = 1.277
Revenue TTM = 86.2m EUR
EBIT TTM = 940.6k EUR
EBITDA TTM = 3.26m EUR
Long Term Debt = 1.64m EUR (from longTermDebt, last quarter)
Short Term Debt = 55.4m EUR (from shortTermDebt, last quarter)
Debt = 57.1m EUR (Calculated: Short Term 55.4m + Long Term 1.64m)
Net Debt = -19.7m EUR (from netDebt column, last quarter)
Enterprise Value = 150.0m EUR (174.7m + Debt 57.1m - CCE 81.8m)
Interest Coverage Ratio = 0.12 (Ebit TTM 940.6k / Interest Expense TTM 8.08m)
FCF Yield = 9.48% (FCF TTM 14.2m / Enterprise Value 150.0m)
FCF Margin = 16.50% (FCF TTM 14.2m / Revenue TTM 86.2m)
Net Margin = -7.58% (Net Income TTM -6.53m / Revenue TTM 86.2m)
Gross Margin = 95.61% ((Revenue TTM 86.2m - Cost of Revenue TTM 3.79m) / Revenue TTM)
Tobins Q-Ratio = -0.40 (set to none) (Enterprise Value 150.0m / Book Value Of Equity -377.7m)
Interest Expense / Debt = 4.20% (Interest Expense 2.40m / Debt 57.1m)
Taxrate = 18.41% (340.0k / 1.85m)
NOPAT = 767.4k (EBIT 940.6k * (1 - 18.41%))
Current Ratio = 1.23 (Total Current Assets 92.8m / Total Current Liabilities 75.2m)
Debt / Equity = 0.82 (Debt 57.1m / last Quarter total Stockholder Equity 69.2m)
Debt / EBITDA = 17.53 (Net Debt -19.7m / EBITDA 3.26m)
Debt / FCF = 4.01 (Debt 57.1m / FCF TTM 14.2m)
Total Stockholder Equity = 77.3m (last 4 quarters mean)
RoA = -4.31% (Net Income -6.53m, Total Assets 151.4m )
RoE = -8.46% (Net Income TTM -6.53m / Total Stockholder Equity 77.3m)
RoCE = 1.19% (Ebit 940.6k / (Equity 77.3m + L.T.Debt 1.64m))
RoIC = 0.55% (NOPAT 767.4k / Invested Capital 139.4m)
WACC = 7.78% (E(174.7m)/V(231.8m) * Re(9.20%)) + (D(57.1m)/V(231.8m) * Rd(4.20%) * (1-Tc(0.18)))
Shares Correlation 5-Years: 10.0 | Cagr: 6.37%
Discount Rate = 9.20% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.77% ; FCFE base≈14.2m ; Y1≈17.5m ; Y5≈29.9m
Fair Price DCF = 8.23 (DCF Value 411.7m / Shares Outstanding 50.0m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: -13.89 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: 130.5
EPS Correlation: 2.21 | EPS CAGR: -47.53%
EPS Growth-of-Growth: -72.80